← Leaderboards
Kathryn M Thrailkill
University Of Kentucky
$1,641,998
Attributed
$1,835,558
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $379.9K · FY2005–17$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$1,835,558 · 7
By mechanism
R01$1,290,000 · 1
R21$387,120 · 1
M01$158,438 · 5
Top collaborators
- Jeffry Stephen Nyman2 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- John L Fowlkes$4,123,467
- Thomas E Curry$22,961,997
- Alan Daugherty$17,452,884
- Ion Deaciuc$987,610
- Jenny Lutshumba$62,521
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchInsulin Dependent Diabetes MellitusHuman SubjectBlood GlucoseDrug Screening /EvaluationPathologic ProcessDiabetic NephropathyFamily GeneticsMetalloendopeptidasesImmunotherapySecretionDisease /Disorder Prevention /ControlDiabetes Mellitus TherapyHyperglycemiaImmunologic Assay /TestDisease /Disorder Proneness /RiskGrowth FactorBasement MembraneHormone TherapyGlucoseExtracellular MatrixGlucose MetabolismClinical TrialsAdolescence (12-20)
Grant awards (16)
Effects of Sodium-dependent Glucose Co-transporter 2 Inhibition on Bone.$167,409
R21 · FY2017 · AR · contact PI
Effects of Sodium-dependent Glucose Co-transporter 2 Inhibition on Bone.$219,711
R21 · FY2016 · AR · contact PI
MATRIX METALLOPROTEINASES IN DIABETIC KIDNEY DISEASE$9,741
M01 · FY2006 · RR · contact PI
Matrix metalloproteinases and diabetic nephropathy$322,500
R01 · FY2005 · DK
MATRIX METALLOPROTEINASES IN DIABETIC KIDNEY DISEASE$57,448
M01 · FY2005 · RR
Matrix metalloproteinases and diabetic nephropathy$322,500
R01 · FY2004 · DK
Matrix Metalloproteinases in Diabetic Kidney Disease$64,791
M01 · FY2004 · RR
Matrix metalloproteinases and diabetic nephropathy$322,500
R01 · FY2003 · DK
Matrix metalloproteinases and diabetic nephropathy$322,500
R01 · FY2002 · DK
LONG TERM SAFETY OF INHALED HUMAN INSULIN IN DIABETES$0
M01 · FY2002 · RR
DIABETES PREVENTION TRIAL--TYPE 1$0
M01 · FY2002 · RR
DIABETES PREVENTION TRIAL--TYPE 1$0
M01 · FY2001 · RR
LONG TERM SAFETY OF INHALED HUMAN INSULIN IN DIABETES$0
M01 · FY2001 · RR
DIABETES TYPE 1 PREVENTION TRIAL$26,458
M01 · FY2000 · RR
LONG TERM SAFETY OF INHALED HUMAN INSULIN IN DIABETES$0
M01 · FY2000 · RR
DIABETES PREVENTION TRIAL--TYPE 1$0
M01 · FY2000 · RR